Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Study Suggests Infinity's NSCLC Hsp90 Chaperone Inhibitor May Be Effective in Genetic Subpopulation
October 20, 2010
In the study, out of three patients with ALK gene rearrangements, two responded partially to Infinity's investigational drug IPI-504, and one experienced prolonged stable disease while on the treatment for 7.2 months and had a 24 percent reduction in tumor size.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- ODAC Meeting on Accelerated Approval for Oncologics Raises Questions about Strategies for PGx Drugs
February 16, 2011 / Pharmacogenomics Reporter - After FDA Letter Seeking More Data, Lilly Won't Pursue CDx-Guided Erbitux in NSCLC in the US
May 2, 2012 / Pharmacogenomics Reporter - Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012 / Pharmacogenomics Reporter - Study Supports Early Investigation of Infinity's PGx-Guided HSP90/mTOR Inhibitor Dual Attack Regimen
September 14, 2011 / Pharmacogenomics Reporter - Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC
July 27, 2011 / Pharmacogenomics Reporter